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Streptococcus pyogenes isolates from a tropical region and a subtropical region of Australia with high and low
incidences of severe streptococcal diseases, respectively, were analyzed for speA, speB, and speC gene distri-
butions and NAD-glycohydrolase expression. No direct correlation of these characteristics with a propensity to
cause invasive diseases was observed.
Group A streptococcus (GAS; Streptococcus pyogenes) is
generally considered a mucosal or skin pathogen responsible
for pharyngitis and impetigo. However, the organism can also
cause severe invasive diseases such as necrotizing fasciitis, toxic
shock syndrome, and cellulitis; and the incidences of these
diseases have increased in developed nations (3, 14). Although
the clonal spread of some strains has been noted during some
invasive disease outbreaks (8), this is not always observed (5).
S. pyogenes expresses several excretory proteins which may
have a role in virulence and pathogenesis. Whereas genes for
many of these virulence factors are present in all GAS strains,
other virulence genes have restricted distributions (2, 18, 21).
The correlation between the distribution of speA (the gene for
erythrogenic toxin A) or its expression and the course of strep-
tococcal disease has been investigated and has yielded conflict-
ing results (7, 9, 13, 17, 18, 21). The level of expression of
extracellular cysteine protease (SpeB) was reported to be low
in GAS isolates from patients with severe disease in Canada
(15); however, no such correlation was found in a study per-
formed elsewhere (17).
All GAS strains carry the gene encoding NAD-glycohydro-
lase (NADase). However, only some strains express this en-
zyme (1, 20). Ninety-two percent of GAS strains isolated from
patients involved in an outbreak of GAS infection in Texas
which caused invasive diseases and death produced NADase
(1). In addition, serotype M1 isolates obtained prior to 1988,
i.e., prior to the resurgence of invasive GAS diseases, are
generally negative for NADase production; but M1 isolates
obtained after 1988 are generally positive for this phenotype
(20). These observations suggest a role for NADase in the
pathogenesis of invasive GAS infections.
The Northern Territory (NT) of Australia has the greatest
diversity of GAS strains per capita reported in the world (11,
12). In this region the epidemiology of GAS does not appear to
follow the epidemiological patterns found elsewhere (4, 5).
The rate of streptococcal invasive diseases among the indige-
nous population is five times that among the general popula-
tion, and no single S. pyogenes clone has been shown to be
dominant (5). We now report on the distribution of the genes
for three erythrogenic toxins (speA, speB, and speC) and NA-
Dase activity in GAS strains from the NT and from southwest-
ern Sydney (SWS), a subtropical region. For this study we
selected distinct molecular types of GAS from the two regions
to avoid potential representation of multiple clonal isolates in
the analysis. The isolates were genotyped (vir typed) as de-
scribed by Gardiner et al. (10). Thirty-seven vir types were
detected among GAS strains isolated from cultures of blood
from patients admitted to Royal Darwin Hospital, a major
hospital in the tropical top end of the NT, from 1990 to 1997
for bacteremia (n  35) and necrotizing fasciitis (n  2).
Seventy-three percent of the patients with invasive disease
were of Aboriginal descent. Thirty-eight vir types were de-
tected among GAS strains isolated from patients with uncom-
plicated infections in the same geographic area during the
same period. Thirty-nine vir types were found among isolates
causing invasive and uncomplicated infections in SWS between
1996 and 1999, with six vir types being commonly detected in
patients with both types of infections. These six vir types were
proportionately distributed between patients with the two
types of infections. Thus, for this study, 26 distinct vir types
were obtained from patients with invasive cases of disease and
13 distinct vir types were obtained from patients with nonin-
vasive cases of disease. Thus, the 114 genotypes analyzed in
this study comprised 63 vir types from patients with invasive
cases of disease (necrotizing fasciitis, toxic shock syndrome,
cellulitis, bacteremia) and 51 vir types from patients with un-
complicated infections from the NT and SWS. No dominant
GAS clone was identified among patients with invasive cases of
disease in either region (5; M. Maley et al., unpublished data).
Every isolate within each region had a distinct genotype, as
determined by vir typing. The genotypes of the isolates recov-
ered from patients in the NT represented nearly three-quarters
of the circulating vir types identified in the NT, and the geno-
types of the isolates recovered from patients in SWS repre-
sented 100% of the vir types identified in that region from 1996
to 1999. Apart from selecting for a unique genotype as deter-
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mined by vir typing, no other means of selection was applied to
either of the sets of isolates.
The GAS isolates were grown in Todd-Hewitt broth supple-
mented with 0.02% yeast extract and 20 mM glycine at 37°C,
and DNA was extracted as described previously (6, 12).
Screening for speA, speB, and speC was carried out by PCR as
described previously (7, 19). The isolates of all vir types pos-
sessed the speB gene, confirming the results of studies with
strains from other geographic areas (22). The distributions of
speA or speC among the isolates from patients with invasive
and noninvasive cases of disease in the NT and in the SWS
region were not significantly different (Table 1). Thus, it ap-
pears that the presence of speA or speC does not correlate with
severe invasive diseases in the two areas of Australia where
isolates for the present study were recovered, one with tropical
climatic conditions and the other with subtropical climatic con-
ditions. Large numbers of distinct GAS strains are circulating
in both regions, and the populations of these two areas have
disparately different life-styles and socioeconomic conditions.
To measure NADase activity in culture supernatants, over-
night cultures of GAS were clarified by centrifugation at 2,000
 g for 10 min. The assay mixture contained 25 l each of 100
mM potassium phosphate buffer (pH 7.3) with 0.1% bovine
serum albumin (Sigma), GAS culture supernatant, and NAD
(1.8 mg/ml; Sigma). The mixture was poured into the wells of
96-well plates. After incubation at 37°C in 5% CO2 for 20 min,
50 l of 5 M NaOH was added to each well and the plates were
incubated in the dark for 1 h at room temperature. Fluores-
cence was measured (excitation, 360 nm; emission, 508 nm) in
a microplate fluorescence reader (FL600; BioTek). The nega-
tive control contained 25 l of growth medium in place of
culture supernatant in the assay mixture. All samples were
assayed in duplicate. A standard curve for the NADase assay
was established with commercial NADase (Sigma). NADase-
positive strains decreased the amount of NAD in the assay
mixture by greater than 30% and were easily distinguished
from the negative strains by this assay. Our results, which
demonstrated a lack of association between NADase activity
and a propensity to cause invasive diseases (Table 1), are in
contrast to the results of an earlier study (1). It is possible that
host factors and clonal spread (or the lack of it) could explain
the contrasting results, but a lack of typing information in the
earlier study (1) prevents an appraisal.
Interestingly, overall a significantly greater proportion of the
SWS strains than the NT strains were found to harbor the speC
gene (51 versus 24%, respectively; P  0.0034) or express
NADase (77 versus 45%, respectively; P  0.0013), and the
results appear to show an inverse correlation between these
characteristics and the incidence of severe diseases, as the
overall crude incidence of severe GAS-associated diseases in
the NT (9.3 per 100,000 population per year [5]) is higher than
that in SWS (1.45 per 100,000 population per year [Maley et
al., unpublished]). Cytolysin-mediated delivery of NADase
into host cells (16), the ability of NADase to induce cellular
changes through cyclic ADP-ribose synthesis, and other recent
studies (1, 20) implicitly attribute a role for this enzyme in the
pathogenesis of invasive diseases. However, the work de-
scribed here does not lend support to such a simple interpre-
tation. Contributions of host and other bacterial factors may be
important in influencing the disease outcomes.
In summary, while we have not observed a correlation be-
tween the distribution of speA or speC or NADase expression
and GAS-associated invasive diseases in two locations in Aus-
tralia, the significantly higher proportions of speC- and NA-
Dase-positive strains from SWS (where there is a relatively low
incidence of GAS-associated invasive diseases) than among
strains from the NT (where there is a relatively high incidence
of GAS-associated invasive diseases) remain unexplained.
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AUTHORS’ CORRECTIONS
NAD-Glycohydrolase Production and speA and speC Distribution in
Group A Streptococcus (GAS) Isolates Do Not Correlate with
Severe GAS Diseases in the Australian Population
Armando DelVecchio, Michael Maley, Bart J. Currie, and K. S. Sriprakash
Menzies School of Health Research and Co-operative Research Centre for Aboriginal and Tropical Health,
Darwin, Queensland Institute of Medical Research, Brisbane, and South Western
Area Pathology Services, Liverpool, Sydney, Australia
Volume 40, no. 7, p. 2642–2644, 2002. Page 2643, column 1: The first sentence of the second full paragraph should be deleted
and replaced with the following text. “The NADase activity in culture supernatants was measured as described by Lutticken et al.
(15a), with a few modifications (see below). Overnight cultures of GAS were clarified by centrifugation at 2,000  g for 10 min.”
Page 2644: The following reference was inadvertently omitted.
15a. Lu¨tticken, R., D. Lu¨tticken, D. R. Johnson, and L. W. Wan-
namaker. 1976. Application of a new method for detecting
streptococcal nicotinamide adenine dinucleotide glycohydro-
lase to various M types of Streptococcus pyogenes. J. Clin.
Microbiol. 3:533–536.
Detection of Smallpox Virus DNA by LightCycler PCR
Mark J. Espy, Franklin R. Cockerill III, Richard F. Meyer, Michael D. Bowen,
Gregory A. Poland, Ted L. Hadfield, and Thomas F. Smith
Division of Clinical Microbiology, Division of Infectious Diseases, and Division of General Internal Medicine, Mayo Clinic
and Foundation, Rochester, Minnesota; Centers for Disease Control and Prevention, Atlanta, Georgia;
and Armed Forces Institute of Pathology, Walter Reed Army Medical Center, Washington, D.C.
Volume 40, no. 6, p. 1985–1988, 2002. Page 1985: The nucleic acid sequences of the primer that was used to amplify the smallpox
virus hemagglutinin gene target (GenBank accession no. M14783) and of the probe that was used in the assay are as follows: for
the primer, 5-CTA ATA TCA TTA GTA TAC GCT ACA C-3 (sense) and 5-GAG TCG TAA GAT ATT TTA TCC-3
(antisense), and for the probe, 5-AAT GAT TAT GTT GTT ATG AGT GCT TG-fluorescein-3 and 5-RED 640-TAT AAG
GAG CCC AAT TCC ATT ATT CT-PHOS-3.
4405
